Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

New HTA Methodology Could Solve Value Conundrum

A new methodology for evaluating the benefits of new medicines aims to make funding decisions more transparent and structured. It could also offer an alternative to the way health technology appraisals reflect value.

Cost Effectiveness Health Technology Assessment

Brazil Needs Better Orphan Drug Policies, Says Alexion

Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.

Market Access Pricing Debate

Janssen Deal Could Signal Clinical Trial Revival In Argentina

Janssen’s commitment to invest more in clinical research in Argentina could be a sign that new regulations are bringing back clinical research to the country.

Clinical Trials Argentina

Is Europe’s BeNeLuxA Coalition Moving Too Fast?

The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.

Europe BioPharmaceutical

Sanofi Is Aiming For European Accelerated Assessment For Sleeping Sickness Drug

Sanofi will this week learn whether fexinidazole, the drug the company is developing for sleeping sickness, will be evaluated quickly once it files for approval. The European Medicines Agency’s CHMP is considering this week whether to grant the company’s request for accelerated assessment.

BioPharmaceutical Infectious Diseases

Australia’s Provisional Approval Pathway Prompts Industry Concerns Over Data Provision

Pharmaceutical industry responses to a consultation by Australia’s Therapeutic Goods Administration on a provisional approval pathway have revealed concerns over whether companies will be able to provide adequate data. Companies have also advised the TGA to look to other regulators, including the European Medicines Agency, for inspiration.

BioPharmaceutical Drug Approval Standards
See All
Advertisement
UsernamePublicRestriction

Register